Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
M. J. Joyner et al.
Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Medicine, General & Internal
Stephen A. Klassen et al.
Summary: Studies show that COVID-19 convalescent plasma can lower mortality rates in patients, especially when administered early and with higher antibody titers.
MAYO CLINIC PROCEEDINGS
(2021)
Article
Medicine, General & Internal
Jonathon W. Senefeld et al.
Summary: This study provides insight into the demographic, geographical, and chronological characteristics of patients in the US Expanded Access Program for COVID-19 convalescent plasma, as well as key safety metrics following plasma transfusion. The majority of patients were male and over 60 years old with a high prevalence of overweight or obesity, and there was significant inclusion of minorities and underserved populations. The EAP was able to provide widespread access to convalescent plasma across all 50 states with low incidence of serious adverse events.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Multidisciplinary Sciences
Leonidas Stamatatos et al.
Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.
Article
Multidisciplinary Sciences
Katie L. Kunze et al.
Summary: Successful COVID-19 therapeutics and vaccines have utilized the immune response to the virus, but locally-evolving variants may impact treatment effectiveness. Near-sourced convalescent plasma has higher efficacy in causing death within 30 days of transfusion.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Michael A. Thompson et al.
Summary: This study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19. Results showed that convalescent plasma treatment was associated with improved 30-day mortality, especially in patients requiring intensive care unit admission or mechanical ventilatory support.
Editorial Material
Medicine, Research & Experimental
Arturo Casadevall et al.
JOURNAL OF CLINICAL INVESTIGATION
(2020)
Review
Medicine, Research & Experimental
Evan M. Bloch et al.
JOURNAL OF CLINICAL INVESTIGATION
(2020)
